Response by cytogenetic risk status at baseline
| . | High risk . | Standard risk . | Unknown . | |||
|---|---|---|---|---|---|---|
| KRd (n = 48) . | Rd (n = 52) . | KRd (n = 147) . | Rd (n = 170) . | KRd (n = 201) . | Rd (n = 174) . | |
| Best overall response, n (%)* | ||||||
| CR or better | 14 (29.2) | 3 (5.8) | 56 (38.1) | 11 (6.5) | 56 (27.9) | 23 (13.2) |
| Very good partial response | 15 (31.1) | 11 (21.2) | 55 (37.4) | 66 (38.8) | 81 (40.3) | 46 (26.4) |
| Partial response | 9 (18.8) | 17 (32.7) | 23 (15.6) | 48 (28.2) | 36 (17.9) | 39 (22.4) |
| Progressive disease | 2 (4.2) | 6 (11.5) | 2 (1.4) | 2 (1.2) | 3 (1.5) | 8 (4.6) |
| ORR, n (%)* | 38 (79.2) | 31 (59.6) | 134 (91.2) | 125 (73.5) | 173 (86.1) | 108 (62.1) |
| 95% CI† | 65.0% to 89.5% | 45.1% to 73.0% | 85.4% to 95.2% | 66.2% to 80.0% | 80.5% to 90.5% | 54.4% to 69.3% |
| Odds ratio for KRd vs Rd (95% CI)‡ | 2.919 (1.140-7.470) | 3.805 (1.945-7.443) | 3.987 (2.376-6.690) | |||
| DOR, median mo | 22.2 | 14.9 | 30.4 | 20.4 | 28.6 | 24.3 |
| 95% CI | 16.0-29.4 | 9.9-24.0 | 24.9 to NE | 13.9-30.5 | 15.0 to NE | 12.0 to NE |
| . | High risk . | Standard risk . | Unknown . | |||
|---|---|---|---|---|---|---|
| KRd (n = 48) . | Rd (n = 52) . | KRd (n = 147) . | Rd (n = 170) . | KRd (n = 201) . | Rd (n = 174) . | |
| Best overall response, n (%)* | ||||||
| CR or better | 14 (29.2) | 3 (5.8) | 56 (38.1) | 11 (6.5) | 56 (27.9) | 23 (13.2) |
| Very good partial response | 15 (31.1) | 11 (21.2) | 55 (37.4) | 66 (38.8) | 81 (40.3) | 46 (26.4) |
| Partial response | 9 (18.8) | 17 (32.7) | 23 (15.6) | 48 (28.2) | 36 (17.9) | 39 (22.4) |
| Progressive disease | 2 (4.2) | 6 (11.5) | 2 (1.4) | 2 (1.2) | 3 (1.5) | 8 (4.6) |
| ORR, n (%)* | 38 (79.2) | 31 (59.6) | 134 (91.2) | 125 (73.5) | 173 (86.1) | 108 (62.1) |
| 95% CI† | 65.0% to 89.5% | 45.1% to 73.0% | 85.4% to 95.2% | 66.2% to 80.0% | 80.5% to 90.5% | 54.4% to 69.3% |
| Odds ratio for KRd vs Rd (95% CI)‡ | 2.919 (1.140-7.470) | 3.805 (1.945-7.443) | 3.987 (2.376-6.690) | |||
| DOR, median mo | 22.2 | 14.9 | 30.4 | 20.4 | 28.6 | 24.3 |
| 95% CI | 16.0-29.4 | 9.9-24.0 | 24.9 to NE | 13.9-30.5 | 15.0 to NE | 12.0 to NE |
Determined by Independent Review Committee according to International Myeloma Working Group Uniform Response Criteria. Patients evaluated for ORR had a best overall response of partial response or better.
Clopper-Pearson interval.
The odds ratio and 95% CI were estimated using the Mantel-Haenszel method.